Kura Oncology to Present First Ziftomenib-FLT3 Inhibitor Combination Trial Data at ASH 2026
Bitget2026/11/04 14:12- Kura Oncology and Kyowa Kirin will present initial ziftomenib-FLT3 inhibitor combination results at ASH Dec. 12-15, 2026, in New Orleans.
- Trials evaluate ziftomenib with quizartinib in newly diagnosed AML or gilteritinib in relapsed or refractory disease, targeting NPM1/FLT3 co-mutated patients.
- Longer-term frontline results with venetoclax and azacitidine support the ongoing Phase 3 KOMET-017 registrational trial; findings will be presented at the meeting.
- An exploratory analysis indicates ziftomenib activity beyond NPM1-mutated and KMT2A-rearranged AML, supporting investigation in additional molecularly defined patient groups.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
